Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers

Oncogenesis

Volumn 3, Issue , 2014, Pages

  Elliman, S J ^a   Howley, B V ^b   Mehta, D S ^c   Fearnhead, H O ^b   Kemp, D M ^d   Barkley, L R ^b  

^a Orbsen Therapeutics Ltd   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c BIOGEN   (United States)

^d Emerald Bio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MICRORNA; MICRORNA 206; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MESSENGER RNA;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; COMPUTER MODEL; DEFENSE MECHANISM; EPITHELIUM CELL; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; ANIMAL CELL; BREAST CANCER CELL LINE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE REPRESSION; LNCAP CELL LINE; MALE; NEOPLASM; NUCLEOTIDE BINDING SITE; ONCOGENE CYCLIN D1; PROSTATE EPITHELIUM CELL; TUMOR SUPPRESSOR GENE;

EID: 84907302433     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.26     Document Type: Article

References (27)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866. (Pubitemid 44629897)
3. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688. (Pubitemid 47552092)
4. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451147-152.
5. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006; 174: 677-687. (Pubitemid 44306724)
6. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007; 21: 1132-1147. (Pubitemid 46984764)
7. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 2008; 68: 5004-5008.
8. Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 2009; 284: 31921-31927.
9. Wang X, Ling C, Bai Y, Zhao J. MicroRNA-206 is associated with invasion and metastasis of lung cancer. Anat Rec (Hoboken) 2011; 294: 88-92.
10. Zhang T, Liu M, Wang C, Lin C, Sun Y, Jin D. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res 2011; 31: 3859-3863.
11. Alteri A, De Vito F, Messina G, Pompili M, Calconi A, Visca P et al. Cyclin D1 is a major target of miR-206 in cell differentiation and transformation. Cell Cycle 2013; 12: 3781-3790.
12. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7: 812-821. (Pubitemid 23163585)
13. Ewen ME, Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 2004; 10: 158-162. (Pubitemid 38410973)
14. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adeno-sines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20. (Pubitemid 40094598)
15. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500. (Pubitemid 40617277)
16. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005; 23: 4215-4224. (Pubitemid 46211327)
17. Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 2006; 20: 2513-2526. (Pubitemid 44396837)
18. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003; 11: 695-707. (Pubitemid 36385123)
19. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996; 12: 2315-2324. (Pubitemid 26192711)
20. Foster JS, Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996; 10: 488-498. (Pubitemid 26142575)
21. Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M et al. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 2006; 95: 185-194.
22. Wang J, Wang Q, Cui Y, Liu ZY, Zhao W, Wang CL et al. Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol 2012; 106: 473-484.
23. Wei M, Zhu L, Li Y, Chen W, Han B, Wang Z et al. Knocking down cyclin D1b inhibits breast cancer cell growth and suppresses tumor development in a breast cancer model. Cancer Sci 2011; 102: 1537-1544.
24. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 803-806. (Pubitemid 29086730)
25. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998; 35: 95-101. (Pubitemid 28183291)
26. Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009; 138: 673-684.
27. Barkley LR, Palle K, Durando M, Day TA, Gurkar A, Kakusho N et al. c-Jun N-terminal kinase-mediated Rad18 phosphorylation facilitates Poleta recruitment to stalled replication forks. Mol Biol Cell 2012; 23: 1943-1954.